Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double-blind, placebocontrolled,
|
|
- Marvin Cook
- 5 years ago
- Views:
Transcription
1 British Journal of Clinical Pharmacology DOI: /j x Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double-blind, placebocontrolled, randomized study M. R. Safarinejad & S. Y. Hosseini Urology Nephrology Research Centre, Shaheed Beheshti University of Medical Sciences, Tehran, Iran Correspondence M. R. Safarinejad MD, PO Box , Tehran, Iran. Tel: Fax: safarinejad@unrc.ir Keywords bladder, detrusor overactivity, tramadol, treatment, urinary incontinence Received 26 July 2005 Accepted 3 November 2005 Published OnlineEarly 14 February 2006 Aim To evaluate the efficacy and safety of tramadol in patients with idiopathic detrusor overactivity (IDO). Methods A total of 76 patients 18 years or older with IDO were randomly assigned to receive 100 mg tramadol sustained release (group 1, n = 38) or placebo (group 2, n = 38) every 12 h for 12 weeks. Clinical evaluation was performed at baseline and every 2 weeks during treatment. All patients underwent urodynamics and ice water test at baseline and 12-week treatment. Main outcome measures were number of voids per 24 h, urine volume per void and episodes of urge incontinence per 24 h on a frequency volume chart and detailed recording of adverse effect. Results After 12 weeks of treatment mean number of voids per 24 h ± SD decreased from 9.3 ± 3.2 to 5.1 ± 2.1 (P < vs. placebo) [95% confidence interval (CI) ]. At that time mean urine volume per void increased from 158 ± 32 to 198 ± 76 ml (P < vs. placebo) (95% CI 8-22), while mean number of incontinence episodes per 24 h decreased from 3.2 ± 3.3 to 1.6 ± 2.8 (P < vs. placebo) (95% CI 2-0.3). Tramadol induced significant improvements in urodynamic parameters. More adverse effects were associated with tramadol treatment than with placebo (P < 0.05). The main adverse event with tramadol was nausea. Conclusions In patients with non-neurogenic IDO tramadol provided beneficial clinical and urodynamic results. Further studies are required to draw final conclusions on the efficacy of this drug in IDO. Introduction The International Continence Society has updated the terminology of the symptoms, signs, urodynamic observations and conditions associated with lower urinary tract dysfunction [1]. Overactive bladder (OAB) is one with inappropriate and involuntary contractions, causing urgency, frequency and/or urinary incontinence. It has an overall prevalence of 16% in Western Europe [2] and 17% in the USA [3]. Idiopathic detrusor overactivity (IDO) is defined as detrusor overactivity with no known precipitating cause [4]. Detrusor contractility is mediated by cholinergic muscarinic receptors; therefore, antimuscarinic agents are often used for treatment of IDO. Their therapeutic efficacy is limited by their troublesome side-effects resulting in the discontinuation of treatment in a signif- Br J Clin Pharmacol 61: The Authors Journal compilation 2006 Blackwell Publishing Ltd
2 Tramadol for treatment of detrusor overactivity icant number of patients [5, 6]. The development of new drugs should therefore target alternative pathways affecting detrusor overactivity. Tramadol is a centrally acting analgesic with two distinct mechanisms of action: one enantiomer exerts a predominantly weak µ opioid effect, whereas the other inhibits noradrenaline and serotonin reuptake, activating descending monoaminergic inhibitory pathways [7]. The effect of the non-opioid component of tramadol is mediated through α 2 -agonistic and serotoninergic activities, by inhibiting the re-uptake of noradrenaline and 5- hydroxytryptamine (5-HT) [8]. There is evidence that unmyelinated C fibres become predominant in mediating detrusor reflex in cases of chronic spinal cord lesions [9] and possibly in idiopathic detrusor hyperactivity [10]. C fibre hyperactivity of the bladder has been identified in patients with detrusor overactivity due to various nonspinal lesions [11]. Through desensitization of sensory fibres by capsaicin or resiniferatoxin the micturition reflex mediated by C fibres can be suppressed and detrusor overactivity can be successfully treated [12, 13]. In a study by Carlsson and Jurna [14], the effects of tramadol on motor and sensory responses of the spinal nociceptive system were tested in the rat. Tramadol at 100 and 200 µg injected intrathecally depressed both the spontaneous activity in ascending axons and their activities because of stimulation of C fibres and activation from Aδ fibres in the sural nerve. Tramadol also inhibits the function of cholinergic receptors, such as muscarinic M 1 and M 3 receptors [15, 16]. Tramadol was found to inhibit micturition in rats at doses below that resulting in analgesia [17]. Recently, Pehrson et al. [18] demonstrated that tramadol effectively suppresses apomorphine-induced IDO in doses shown to have analgesic activity in rats. This supports a dopaminergic mechanism. Tramadol may be acting on IDO through several mechanisms, namely inhibition of cholinergic muscarinic receptors, inhibition of serotonin and noradrenaline reuptake with resultant bladder relaxation through stimulation of β-adrenoceptors, changes in dopamine receptor activation and/or stimulation of µ- and δ-opioid. Opening of ATP-sensitive K + -channels (K ATP ) in smooth muscle cells will lead to potassium efflux and hyperpolarization, which in turn leads to reduced opening probability of Ca 2+ channels and thus decreased influx of calcium. The use of K ATP channel openers has shown such inhibitory effects in the detrusor of several species [19, 20]. Thus K ATP channel openers may be an attractive way of treating bladder overactivity, by eliminating unwanted contraction during the filling phase. It has also been known that the modulation of both K + channels and nitrergic pathways has a role in the perception of pain and the effects of analgesics. More recently, Yalcin et al. [21] demonstrated that nonspecific voltage-dependent K + channels and nitrergic systems may have a role in the antinociceptive effects of tramadol in hot-plate test in mice. These rationales and pharmacological properties prompted us to investigate the urodynamic and clinical effects of oral tramadol in the treatment of IDO. Materials and methods Seventy-six patients aged 18 years with cystometrically proved detrusor overactivity (idiopathic instability or detrusor hyperreflexia, or uninhibited phasic detrusor contractions with an amplitude of 10 cm H 2 O) and average urinary frequency of eight or more voids per 24 h on the baseline frequency volume chart entered the study. None of the patients had received other treatment for IDO for at least 4 weeks before the start of the study. The methods of urodynamic study were in accordance with the recommendations of the International Continence Society [22]. All subjects gave informed consent and the study protocol and questionnaire were reviewed and approved by local ethics committees. All patients underwent preliminary assessment, including a medical history, physical examination, serum chemistries, urinalysis, urine culture and assessment of urinary tract by intravenous urography (IVU) and voiding cystourethrography (VCUG). In urodynamic studies, first uninhibited detrusor contraction, maximum bladder capacity and maximum pressure of uninhibited detrusor contractions were recorded. The bladder was emptied with a 12-Fr Nélation s catheter. Urodynamics were done with a six-channel urodynamic apparatus using a three-way 8- Fr cystometry catheter and a 12-Fr all silicone double lumen rectal balloon catheter. The urethral pressure was sited at the highest basic pressure and calculated constantly during filling. The urodynamic catheters were fixed on the body surface with adhesive tape and their location repeatedly checked on radioscopy. Continuous bladder filling was done at 30 ml min 1 with sterile contrast media at body temperature with patients sitting. Patients were asked to report and explain all sensations they experienced in the bladder during filling. During the course of cystometry, the following four bladder characteristics were recorded: (i) capacity, (ii) sensation, (iii) compliance and (iv) the occurrence of involuntary contractions. Exclusion criteria included stress urinary inconti- Br J Clin Pharmacol 61:4 457
3 M. R. Safarinejad & S. Y. Hosseini nence (urine escaping from urethra during coughing when the bladder was stable), maximum flow rate <10 ml s 1, postvoid residual urine >20% of functional bladder capacity, urinary tract infection, any proved lower urinary tract disease, intermittent catheterization, average total voided volume >3000 ml per 24 h and, for women, being perimenopausal or menopausal. Each eligible patient was given a randomization number using an interactive voice response system, which followed a randomization table generated by the method of random permuted blocks [23]. Persons who were geographically and operationally independent of the study investigator did the randomization of the study. During a 4-week wash-out and run-in period patients were given a diary and requested to record accurately the frequency volume chart. Patients were randomly assigned to receive either 100 mg tramadol sustained release (Tramadol LP) twice daily (group 1) or placebo (group 2) for 12 weeks. Sustained-release tablets release the active ingredient over a period of 12 h, and have a bioavailability of 87 95% compared with capsules [17]. Peak plasma concentrations (C max ) in urine occurred at nearly the same time as in plasma. The urine concentrations are 43- to 46-fold higher than the corresponding plasma concentrations [24]. Tramadol is mainly excreted via kidneys (approximately 90%) [25]. The mean elimination half-life is about 5 6 h [24]. To accomplish blinding of the medication, the pharmacy prepared identical-appearing capsules of 100 mg sustained release tramadol and placebo before randomization. According to the manufacturer, tramadol and placebo were indistinguishable as to appearance, colour and flavour. Patients were seen at entry, at baseline after run-in, and after 2, 4, 6, 8 and 12 weeks of treatment. Dose reduction was not permitted. Efficacy was assessed using 2-week voiding diaries. The primary end-point was the change in the number of episodes of urge incontinence per 24 h. Secondary end-points included changes in number of voids per 24 h and volume of urine per void. The efficacy of the placebo and tramadol was also assessed every 2 weeks during treatment and at the end of the 12-week treatment, by determining the proportion of patients who achieved normal voiding frequency (less than eight voids per 24 h), complete response of incontinence (complete dryness on voiding diary chart) or complete response (less than eight voids per 24 h and complete dryness on the chart). For subjective judgement of improvement of bladder symptoms we used a 6-point Likert scale at baseline and week 12 [26]. Patients rated the bladder condition with choices between my bladder condition does not cause me any problems at all and my bladder condition causes me very severe problems on a scale of: 0, no problems; 1, very minor problems; 2, minor problems; 3, moderate problems; 4, severe problems; and 5, many severe problems. Post-treatment improvement in symptoms was defined as a score decrease of 1 point. Statistical analysis The study sample size of 76 patients (38 per group) was powered for a difference of approximately 1 SD between the tramadol and placebo group with a 95% confidence interval (α = 0.05) a statistical power of 85% (β = 0.15) and assuming an overall 10% dropout rate. All efficacy measures were evaluated by comparing baseline values with those obtained after 12 weeks of treatment. Intention-to-treat analyses were performed on all efficacy variables. Data were expressed as mean ± SD. As data were not always normally distributed, nonparametric tests (Kruskal Wallis test, Mann Whitney Wilcoxon test or Wilcoxon signed rank test for paired test comparing a change to 0) were used to test the relations.the independent sample two-tailed t-test was used to compare the efficacy variables by tramadol and placebo. Comparison of the incidence of side-effects, percentages of patients with normalized voiding frequency, complete response of incontinence and complete response was made using the χ 2 test. The level of significance was defined as α = 0.05 (two-sided). For voiding variables we also calculated 95% confidence intervals (CIs) for the differences among treatment groups in the mean change from baseline. Statistical analysis was performed using the computer statistical package SPSS release for Windows (SPSS, Chicago, IL, USA; 1999) and SAS/6.4 (SAS Institute Cary, NC, USA). Results Seventy-six patients were recruited, but only 69 (91%) completed the whole randomized trial study. Of these, seven withdrew from the study before week 12, including four (10.5%) on placebo and three (8%) on tramadol. Reasons for noncompletion included two adverse effects (tramadol group), three lack of effect on IDO (placebo group) and two lost to follow-up (one from each group). The difference in dropout rates was not significant between the groups. At baseline, the study and placebo groups were similar in demographic and clinical characteristics (Table 1). The subjects were evaluated at baseline, every 2 weeks during treatment and at the end of the 12-week treatment. The beneficial effects of tramadol were :4 Br J Clin Pharmacol
4 Tramadol for treatment of detrusor overactivity Table 1 Patient characteristics Variables apparent at the end of the 2-week treatment and continued throughout the 12-week treatment period. Table 2 shows voiding variables at baseline and at 12 weeks treatment. Patients receiving tramadol demonstrated a significant decrease in the number of voids Tramadol n = 35 Placebo n = 34 Demographics Mean age, years (range) 39 (21 59) 37 (19 57) NS Men:women (%) 31 : : 67 NS Median weight, kg (range) 56 (48 81) 54 (49 79) NS Clinical characteristics, % Mean ± SD duration of symptoms (years) 5 ± ± 2.8 NS Mean ± SD urge incontinence episodes per 24 h 3.2 ± ± 3.1 NS Mean ± SD voids per 24 h 9.3 ± ± 3.1 NS Mean ± SD urine volume per void (ml) 158 ± ± 28 NS NS, Not significant. Table 2 Voiding and urodynamic variables at baseline and after 12 weeks of treatment Variables Tramadol Placebo P-value 95% CI* P-value At baseline Mean ± SD volume per void (ml) 158 ± ± 28 NS Mean ± SD no of incontinence episodesper 24 h 3.2 ± ± 3.1 NS Mean ± SD no of voidsper 24 h 9.3 ± ± 3.1 NS Patients with incontinence, n (%) 15 (42.9) 13 (38.2) NS Mean ± SD volume at initial contraction (ml) 152 ± ± 36 NS Mean ± SD max. bladder capacity (ml) 178 ± ± 68 NS Mean ± SD max. pressure of uninhibited detrusor 46 ± ± 16 NS contractions (cm H 2 O) Mean ± SD postvoid residual vol. (ml) 33 ± ± 17 NS At 12-week treatment schedule Mean ± SD volume per void (ml) 198 ± ± 31 <0.001 (8-22) Mean ± SD no of incontinence episodes per 24 h 1.6 ± ± 3.0 <0.001 ( 2-0.3) Mean ± SD no of voids per 24 h 5.1 ± ± 3.2 <0.001 ( ) Patients with incontinence, n (%) 5 (14.3) 13 (38.2) <0.05 (7-15) Mean ± SD vol. at initial contraction (ml) 228 ± ± 41 <0.01 (14-28) Mean ± SD max. bladder capacity (ml) 252 ± ± 56 <0.05 (12-24) Mean ± SD max. pressure of uninhibited detrusor 31 ± ± 16 <0.01 (5-19) contractions (cm H 2 O) Mean ± SD postvoid residual vol. (ml) 31 ± ± 20 NS NS, Not significant.*95% confidence Interval. per 24 h compared with those receiving placebo. Mean ± SD pretreatment numbers of voids per 24 h were 9.3 ± 3.2 and 9.6 ± 3.1 in groups 1 and 2, respectively. They decreased to 5.1 ± 2.1 and 8.7 ± 3.2, respectively (P < 0.001) (95% CI ). This benefit continued Br J Clin Pharmacol 61:4 459
5 M. R. Safarinejad & S. Y. Hosseini throughout the treatment period (Figure 1). The mean pretreatment urine volume was 158 ± 32 and 151 ± 28 ml per void in groups 1 and 2, respectively. The mean of urine volume per void was 198 ± 76 and 159 ± 31 ml in the tramadol and placebo groups, respectively (P < 0.001) (95% CI 8-22). This benefit also continued throughout the treatment period (Figure 2). For the number of episodes of urge incontinence per 24 h tramadol was more effective than placebo in decreasing incontinence. The baseline mean number of incontinence episodes per 24 h decreased from 3.2 ± 3.3 and 3.3 ± 3.1 to 1.6 ± 2.8 and 3.1 ± 3 at 12 weeks treatment in groups 1 and 2, respectively (P < 0.001) (95% CI 2-0.3) (Table 2, Figure 3). Normalizing voiding frequency was achieved in significantly more patients on tramadol than on those on placebo (63% vs. 14%, χ 2 test P < 0.001). Before treatment, 28 (41%) of the 69 patients reported having incontinence. Complete urinary continence was achieved by Change from baseline in mean number of micturition\24 hours Change from baseline in mean volume voided/micturition (ml) Baseline Week 2 Week 4 Week 6 Week 8 Week 10 Week of the 15 patients (mean age 29.6 years) at the end of treatment with tramadol. Urinary continence was not achieved in 13 out of 13 patients (mean age 28.8 years) with placebo (P < 0.001) (95% CI 7-15). Complete response was achieved in 29% of women who received tramadol. There was no complete response at the end of the placebo study (P < 0.001). Table 2 shows the urodynamic parameters at baseline and at 12 weeks treatment. The mean pretreatment threshold in the first uninhibited detrusor contraction was markedly increased from baseline (152 ± 43 ml) in the tramadol group to 228 ± 38 ml compared with only a gradual and mild increase in the placebo group (from 157 ± 36 to 164 ± 41 ml) (P < 0.01) (95% CI 14-28). The mean pretreatment maximum bladder capacity was 178 ± 61 ml for tramadol compared with 173 ± 68 ml for placebo. Tramadol was superior in increasing mean maximum bladder capacity. The mean maximum bladder capacity at 12 weeks treatment was 252 ± 98 and Figure 1 Mean change from baseline in number of voids per 24 h. Tramadol ( ), placebo ( ) Figure 2 Mean change from baseline in mean urine volume per void. Tramadol ( ), placebo ( ) 0 Baseline Week 2 Week 4 Week 6 Week 8 Week 10 Week :4 Br J Clin Pharmacol
6 Tramadol for treatment of detrusor overactivity Figure 3 Mean change from baseline in mean number of incontinence episodes per 24 h. Tramadol ( ), placebo ( ) Table 3 Adverse events n, Tramadol (patients %) n, Placebo 2 (patients %) P-value Adverse events 13 (34) 6 (15.8) <0.05 Nausea 7 (18.4) 2 (5.3) <0.05 Vomiting 3 (7.9) 2 (5.3) NS Dizziness 2 (5.3) 1 (2.6) NS Constipation 1 (2.6) 0 NS NS, Not significant. Change from baseline in mean number of incontinence episodes\24 hours Baseline Week 2 Week 4 Week 6 Week 8 Week 10 Week ± 56 ml for tramadol and placebo, respectively (P < 0.05) (95% CI 12-24). The baseline and 12-week mean maximum pressures of uninhibited detrusor contractions were 46 ± 14, 42 ± 16 cm H 2 O and 31 ± 18, 37 ± 16 cm H 2 O in groups 1 and 2, respectively. The tramadol group showed a significantly decreased mean maximum pressure of uninhibited detrusor contractions than that in the placebo group (P < 0.01) (95% CI 5-19). For the subjective evaluation of problems relating to the bladder conditions, 68% and 18% of patients who received tramadol and placebo, respectively, reported an improvement (P < 0.05). More adverse effects were associated with tramadol treatment (P < 0.05) ( Table 3). Thirty-four percent and 16% in the tramadol and placebo groups, respectively, reported adverse events. Nausea was the most frequently reported adverse event in the tramadol group, as noticed by seven (18.4%) patients. Both tramadol- and placeboassociated side-effects were mild in affected patients but two patients in the tramadol group dropped out of the study because of nausea. Discussion Tramadol is widely used as an analgesic. For moderate pain it is as effective as morphine, without the respiratory depression associated with opioids [27]. Morphine is effective in blocking micturition reflexes within the central nervous system [28] and reuptake inhibitors of noradrenaline and/or 5-HT can influence micturition [29]. Detrusor overactivity in, for example, Parkinson s disease and cerebral infarction may be due to changes in dopamine receptor activation. In a rat model of detrusor overactivity due to such changes, tramadol abolished the response to dopamine receptor stimulation [21]. In a recent study it was also found that tramadol normalized detrusor overactivity in middle cerebral arteryoccluded rats [30]. During the last decade there have been many efforts to provide therapeutic alternatives to standard anticholinergics in the treatment of IDO. Our study represents the first observation of the effects of tramadol on bladder function in humans. IDO is a common and troublesome condition. To our knowledge, an effective and well-tolerated medication for treating IDO is not yet available. Our placebocontrolled trial demonstrates that sustained release tramadol at doses of 100 mg twice daily is efficacious with respect to frequency volume chart parameters. Clinical onset of the effect of tramadol was rapid. Patients achieved approximately 70% of the maximum effect within 2 weeks of beginning treatment (Figures 1 3). Br J Clin Pharmacol 61:4 461
7 M. R. Safarinejad & S. Y. Hosseini This finding is useful, since after patients achieve symptomatic relief they may tolerate better fluid intake, as shown by the improved volume per void. In this study tramadol induced a significant decrease in first uninhibited detrusor contraction (P < 0.01) and in maximum bladder capacity (P < 0.05), and a significant decrease in maximum pressure of uninhibited detrusor contractions (P < 0.01) compared with placebo at 12 weeks treatment. As the increase in micturition volume after (±)-tramadol was abolished by pretreatment with naloxone, µ-opioid receptor stimulation was suggested to be the main inhibitory mechanism of (±)- tramadol on normal rat micturition [31]. However, within the brain, opioid, serotonin and noradrenaline pathways are intimately coupled [32], suggesting a potential interaction between opioid and monoaminergic mechanisms in the action of (±)-tramadol. Tramadol was well tolerated and no serious safety concerns were identified. There were few serious adverse events or withdrawals owing to adverse events, which were typically associated with tramadol, namely nausea, which occurred infrequently. Compliance was high in most patients. About 18% (seven) of patients reported nausea. We did not observe any significant difference in the incidence of adverse effects, except for nausea, which occurred significantly more frequently with tramadol. Two patients receiving tramadol withdrew from treatment due to nausea. Given the favourable tolerability profile of tramadol, future trials should evaluate its efficacy and safety with different regimens and doses to improve further the symptoms of detrusor overactivity. In conclusion, tramadol was effective and well tolerated in treating IDO. These promising results should motivate the development of further double-blind, placebo-controlled trials including more patients and a longterm study to confirm our findings and determine the acceptability of this treatment over a longer follow-up. References 1 Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. Standardization Sub-Committee of the International Continence Society: The standardization of terminology of lower urinary tract function recommended by the International Continence Society. Neurourol Urodyn 2002; 21: Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population based prevalence study. BJU Int 2001; 87: Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: Dunn JS Jr, Ellerkmann RM, Bent AE. Pathophysiology of detrusor overactivity. J Pelvic Med Surg 2004; 10: Thüroff J, Bunke B, Ebner A, Faber P, de Geeter P, Hannappel J, Heidler H, Madersbacher H, Melchior H, Schäfer W, Schwenzer T, Stöckle M. Randomized, double blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991; 145: Kelleher CJ, Cardozo LD, Khullar V, Salvatore S, Hill S. Anticholinergic therapy: the need for continued surveillance. Neurourol Urodynam 1994; 13: Marcou TA, Marque S, Mazoit JX, Benhamou D. The median effective dose of tramadol and morphine for postoperative patients: a study of interactions. Anesth Analg 2005; 100: Altunkaya H, Ozer Y, Kargi E, Babuccu O. Comparison of local anaesthetic effects of tramadol with prilocaine for minor surgical procedures. BJA 2003; 90: de Groat WC, Kawatani M, Hisamitsu T, Cheng CL, Ma CP, Thor K, Steers W, Roppolo JR. Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst Suppl 1990; 30: S Silva C, Ribeiro MJ, Cruz F. The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J Urol 2002; 168: Chai TC, Gray ML, Steers WD. The incidence of a positive ice water test in bladder outlet obstructed patients: evidence for bladder neural plasticity. J Urol 1998; 160: Fowler CJ, Jewkes D, McDonald WI, Lynn B, de Groat WC. Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 1992; 16: 339 (8803): Kuo HC. Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions. J Urol 2003; 170: Carlsson KH, Jurna I. Effects of tramadol on motor and sensory responses of the spinal nociceptive system in the rat. Eur J Pharmacol 1987; 139: Sagata K, Minami K, Yanagihara N, Shiraishi M, Toyohira Y, Ueno S, Shigematsu A. Tramadol inhibits norepinephrine transporter function at desipramine-binding sites in cultured bovine adrenal medullary cells. Anesth Analg 2002; 94: Shiga Y, Minami K, Shiraishi M, Uezono Y, Murasaki O, Kaibara M, Shigematsu A. The inhibitory effects of tramadol on muscarinic receptor-induced responses in Xenopus oocytes expressing cloned M(3) receptors. Anesth Analg 2002; 95: Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004; 43: Pehrson R, Andersson KE. Tramadol inhibits rat detrusor overactivity caused by dopamine receptor stimulation. J Urol 2003; 170: :4 Br J Clin Pharmacol
8 Tramadol for treatment of detrusor overactivity 19 Masuda N, Uchida W, Shirai Y, Shibasaki K, Goto K, Takenaka T. Effects of the potassium channel opener YM 934 on the contractile response to electrical field stimulation in pig detrusor smooth muscle. J Urol 1994; 154: Zhou Q, Sutake N, Shibata S. Inhibitory mechanism of nicorandil in isolated rat urinary bladder and femoral artery. Eur J Pharmacol 1995; 273: Yalcin I, Aksu F. Involvement of potassium channels and nitric oxide in tramadol antinociception. Pharmacol Biochem Behav 2005; 80: Griffiths D, Hofner K, van Mastrigt R, Rollema HJ, Spangberg A, Gleason D. Standardization of terminology of lower urinary tract function: pressure flow studies of voiding, urethral resistance, and urethral obstruction. International Continence Society Subcommittee on Standardization of Terminology of Pressure- Flow Studies. Neurourol Urodyn 1997; 16: Fleiss J. The Design and Analysis of Clinical Experiments. New York: John Wiley & Sons Inc. 1986: Lintz W, Beier H, Gerloff J. Bioavailability of tramadol after i.m. injection in comparison to i.v. infusion. Int J Clin Pharmacol Ther 1999; 37: Erlacin S, Frankus E, Uragg H. Biotransformation of tramadol in man and animal [in German]. Arzneimittel Fortramadol Schung 1981; 31: Abram P, Freeman R, Anderström D, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. BJU 1998; 81: Lehmann KA. Le tramadol dans le douleurs argues. Drugs 1997; 53: Dray A, Nunan L. Supraspinal and spinal mechanisms in morphine-induced inhibition of reflex urinary bladder contractions in the rat. Neuroscience 1987; 22: Anderson KE. Treatment of the overactive bladder: possible central nervous system drug targets. Urology 2002; 59: Pehrson R, Stenmanb E, Andersson KE. Effects of tramadol on rat detrusor overactivity induced by experimental cerebral infarction. Eur Urol 2003; 44: Pandita RK, Pehrson R, Christoph T, Friderichs E, Anderson KE. Actions of tramadol on micturition in awake, freely moving rats. Br J Pharmacol 2003; 139: Khachaturian H, Watson SJ. Some perspectives on monoamine opioid peptide interaction in rat central nervous system. Brain Res Bull 1982; 9: Br J Clin Pharmacol 61:4 463
What is on the Horizon in Drug Therapy for OAB?
What is on the Horizon in Drug Therapy for OAB? K-E Andersson, MD, PhD Wake Forest Institute for Regenerative Medicine Wake Forest University School of Medicine Winston Salem, North Carolina Disclosures
More information2/9/2008. Men Women. Prevalence of OAB. Men: 16.0% Women: 16.9% Prevalence (%) < Age (years)
Definition Botox for Overactive Bladder Donna Y. Deng Assistant Professor UCSF Department of Urology Urinary urgency With or without urge incontinence Usually with frequency & nocturia International Continence
More informationOveractive Bladder; OAB. Aδ silent C. Adenosine triphosphate; ATP SD g n Key words
25-32 2009 SD 200-270g n 28 4 1 2 3 4 PE-50 4-5 0.25 60 C Key words acupuncture stimulation overactive bladder rat bladder irritation C C fiber Received November 17, 2008; Accepted January 9, 2009 I Overactive
More informationThe Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence
european urology supplements 5 (2006) 849 853 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence Stefano
More informationAntimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?
Review Article SENSORY ACTIONS OF ANTIMUSCARINICS FINNEY et al. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? STEVEN M. FINNEY, KARL-ERIK
More informationOriginal Article. Annals of Rehabilitation Medicine INTRODUCTION
Original Article Ann Rehabil Med 2014;38(3):342-346 pissn: 2234-0645 eissn: 2234-0653 http://dx.doi.org/10.5535/arm.2014.38.3.342 Annals of Rehabilitation Medicine Phasic Changes in Bladder Compliance
More informationComparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder
European Urology European Urology 48 (2005) 110 115 Female UrologyöIncontinence Comparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder Martin
More informationThis Special Report supplement
...INTRODUCTION... Overactive Bladder: Defining the Disease Alan J. Wein, MD This Special Report supplement to The American Journal of Managed Care features proceedings from the workshop, Overactive Bladder:
More informationGOVINDARAJ N. RAJKUMAR, DOUGLAS R. SMALL, ABDUL W. MUSTAFA and GRAEME CONN Department of Urology, Southern General Hospital, Glasgow, UK
Original Article BTXA IN DETRUSOR FOR REFRACTORY IDIOPATHIC DOA RAJKUMAR et al. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of
More informationNeural Control of Lower Urinary Tract Function. William C. de Groat University of Pittsburgh Medical School
Neural Control of Lower Urinary Tract Function William C. de Groat University of Pittsburgh Medical School Disclosures Current funding: NIH Grants, DK093424, DK-091253, DK-094905, DK-090006. Other financial
More informationURINARY INCONTINENCE. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara
URINARY INCONTINENCE Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara Definition The involuntary loss of urine May denote a symptom, a sign or a condition Symptom the
More informationAnticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
Página 1 de 6 PubMed darifenacin vs solifenacin Display Settings:, Sorted by Recently Added Results: 5 1. Int Urogynecol J. 2013 Oct 25. [Epub ahead of print] Anticholinergic medication use for female
More informationThe Neurogenic Bladder
The Neurogenic Bladder Outline Brandon Haynes, MD Resident Physician Department of Urology Jelena Svircev, MD Assistant Professor Department of Rehabilitation Medicine Anatomy and Bladder Physiology Bladder
More informationEffect of Desmopressin with Anticholinergics in Female Patients with Overactive Bladder
www.kjurology.org DOI:10.4111/kju.2011.52.6.396 Voiding Dysfunction Effect of Desmopressin with Anticholinergics in Female Patients with Overactive Bladder Young Kook Han, Won Ki Lee, Seong Ho Lee, Dae
More informationObjectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS
URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama
More informationDRUG FORECAST. Select Conditions of the Lower Urinary Tract
Transdermal Oxybutynin: Novel Drug Delivery for Overactive Bladder Vitalina Rozenfeld, PharmD, BCPS, Stanley Zaslau, MD, Kathleen New Geissel, PharmD, David Lucas, PhD, and Lili Babazadeh, PharmD INTRODUCTION
More information3/20/10. Prevalence of OAB Men: 16.0% Women: 16.9% Prevalence of OAB with incontinence (OAB wet) Men: 2.6% Women: 9.3% Dry. Population (millions) Wet
1 Prevalence of OAB Men: 16.0% Women: 16.9% Stewart WF, et al. World J Urol. 2003;20:327-336. Prevalence of OAB with incontinence (OAB wet) Men: 2.6% Women: 9.3% Stewart WF, et al. World J Urol. 2003;20:327-336.
More informationOveractive Bladder: Diagnosis and Approaches to Treatment
Overactive Bladder: Diagnosis and Approaches to Treatment A Hidden Condition* Many Many patients self-manage by voiding frequently, reducing fluid intake, and wearing pads Nearly Nearly two-thirds thirds
More informationSummary. Neuro-urodynamics. The bladder cycle. and voiding. 14/12/2015. Neural control of the LUT Initial assessment Urodynamics
Neuro-urodynamics Summary Neural control of the LUT Initial assessment Urodynamics Marcus Drake, Bristol Urological Institute SAFETY FIRST; renal failure, dysreflexia, latex allergy SYMPTOMS SECOND; storage,
More informationInvoluntary Detrusor Contractions: Correlation of Urodynamic Data to Clinical Categories
Neurourology and Urodynamics 20:249±257 (2001) Involuntary Detrusor Contractions: Correlation of Urodynamic Data to Clinical Categories Lauri J. Romanzi, Asnat Groutz, Dianne M. Heritz, and Jerry G. Blaivas*
More informationClinical Study Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive Bladder
Advances in Urology Volume 2009, Article ID 328364, 4 pages doi:10.1155/2009/328364 Clinical Study Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive
More informationTREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH
TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH CONTENTS Overactive bladder (OAB) Treatment of OAB Beta-3 adrenoceptor agonist (Betmiga ) - Panacea? LASER treatment - a flash in the pan or the
More informationPosterior Tibial Nerve Stimulation for Treating Neurologic Bladder in Women: a Randomized Clinical Trial
ORIGINAL ARTICLE Posterior Tibial Nerve Stimulation for Treating Neurologic Bladder in Women: a Randomized Clinical Trial Tahereh Eftekhar 1, Nastaran Teimoory 1, Elahe Miri 1, Abolghasem Nikfallah 2,
More informationTHE ACONTRACTILE BLADDER - FACT OR FICTION?
THE ACONTRACTILE BLADDER - FACT OR FICTION? Jacob Golomb Department of Urology Chaim Sheba Medical Center Tel Hashomer NEUROGENIC UNDERACTIVE DETRUSOR Central (complete/incomplete): Spinal cord injury-
More informationThe International Continence Society
REPORTS Safety and Tolerability of Tolterodine for the Treatment of Overactive Bladder in Adults Richard G. Roberts, MD, JD; Alan D. Garely, MD; and Tamara Bavendam, MD Abstract This article evaluates
More informationGUIDELINES ON URINARY INCONTINENCE
12 GUIDELINES ON URINARY INCONTINENCE (Text updated March 2005) J. Thüroff, (chairman), P. Abrams, K.E. Andersson, W. Artibani, E. Chartier-Kastler, C. Hampel, Ph. van Kerrebroeck Introduction The condition
More information5 Conservative Treatment for. Pelvic Floor Disorders
5 Conservative Treatment for Pelvic Floor Disorders 23 Pharmacologic Approach to Urinary Incontinence and Voiding Disorders K.-E. Andersson Introduction The main components of the lower urinary tract,
More informationLong-Term Safety, Tolerability and Ef cacy of Extended-Release Tolterodine in the Treatment of Overactive Bladder
European Urology European Urology 41 (2002) 588±595 Long-Term Safety, Tolerability and Ef cacy of Extended-Release Tolterodine in the Treatment of Overactive Bladder K. Kreder a,*, C. Mayne b, U. Jonas
More informationUrodynamic Patterns of the Idiopathic Overactive Bladder
Science Journal of Clinical Medicine 2017; 6(5): 74-79 http://www.sciencepublishinggroup.com/j/sjcm doi: 10.11648/j.sjcm.20170605.12 ISSN: 2327-2724 (Print); ISSN: 2327-2732 (Online) Urodynamic Patterns
More informationManagement of Urinary Incontinence in Older Women. Dr. Cecilia Cheon Department of Obs. & Gyn. Queen Elizabeth Hospital
Management of Urinary Incontinence in Older Women Dr. Cecilia Cheon Department of Obs. & Gyn. Queen Elizabeth Hospital Epidemiology Causes Investigation Treatment Conclusion Elderly Women High prevalence
More informationInnovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders
TNe 10 Innovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders Stuart B. Bauer, MD President, ICCS Department of Urology Children s Hospital Boston Professor of Urology Harvard
More informationDiagnosis and Mangement of Nocturia in Adults
Diagnosis and Mangement of Nocturia in Adults Christopher Chapple Professor of Urology Sheffield Teaching Hospitals University of Sheffield Sheffield Hallam University UK 23 rd October 2015 Terminology
More informationStudy No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
More informationNEUROGENIC BLADDER. Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph
NEUROGENIC BLADDER Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph OUTLINE Definition Anatomy and physiology of bladder function Types of neurogenic bladder Assessment and management Complications
More informationCHAPTER 6. M.D. Eckhardt, G.E.P.M. van Venrooij, T.A. Boon. hoofdstuk :49 Pagina 89
hoofdstuk 06 19-12-2001 09:49 Pagina 89 Urethral Resistance Factor (URA) Versus Schäfer s Obstruction Grade and Abrams-Griffiths (AG) Number in the Diagnosis of Obstructive Benign Prostatic Hyperplasia
More information김준철 가톨릭대학교의과대학비뇨기과학교실
비뇨기계자율신경병증의치료 김준철 가톨릭대학교의과대학비뇨기과학교실 Introduction Urologic complications have increasingly become a concern in those affected by DM Genitourinary problems are included among these complications, related
More informationNeural control of the lower urinary tract in health and disease
Neural control of the lower urinary tract in health and disease Jalesh N. Panicker MD, DM, FRCP Consultant Neurologist and Clinical lead in Uro-Neurology The National Hospital for Neurology and Neurosurgery
More informationValidation of a simple patient questionnaire to assist self-detection of overactive bladder
æoriginal PAPER Validation of a simple patient questionnaire to assist self-detection of overactive bladder A study in general practice Arnfinn Seim 1, Trygve Talseth 2, Harriet Haukeland 3, Kjetil Høye
More informationRetrospective Analysis of Efficacy and Tolerability of Tolterodine in Children with Overactive Bladder
European Urology European Urology 45 (2004) 240 244 Retrospective Analysis of Efficacy and Tolerability of Tolterodine in Children with Overactive Bladder A. Raes a,, P. Hoebeke b, I. Segaert a, E. Van
More informationTHE EVOLUTION OF DETRUSOR OVERACTIVITY AFTER WATCHFUL WAITING, MEDICAL THERAPY AND SURGERY IN PATIENTS WITH BLADDER OUTLET OBSTRUCTION
0022-5347/03/1692-0535/0 Vol. 169, 535 539, February 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000045600.69261.73 THE EVOLUTION
More informationImpact of urethral catheterization on uroflow during pressure-flow study
Research Report Impact of urethral catheterization on uroflow during pressure-flow study Journal of International Medical Research 2016, Vol. 44(5) 1034 1039! The Author(s) 2016 Reprints and permissions:
More informationUrinary Incontinence in Women: Never an Acceptable Consequence of Aging
Urinary Incontinence in Women: Never an Acceptable Consequence of Aging Catherine A. Matthews, MD Associate Professor Chief, Urogynecology and Pelvic Reconstructive Surgery University of North Carolina,
More informationPossible Effect of Carbamazepine A Sodium Channel Blocker on Urinary Bladder Dysfunction in Type-1 Diabetic Patients
Med. J. Cairo Univ., Vol. 84, No. 1, March: 85-90, 2016 www.medicaljournalofcairouniversity.net Possible Effect of Carbamazepine A Sodium Channel Blocker on Urinary Bladder Dysfunction in Type-1 Diabetic
More informationHospital and Tzu Chi University, Hualien, Taiwan
LUTS (2012) 4, 29 34 ORIGINAL ARTICLE Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity Yih-Chou
More informationManagement of OAB. Lynsey McHugh. Consultant Urological Surgeon. Lancashire Teaching Hospitals
Management of OAB Lynsey McHugh Consultant Urological Surgeon Lancashire Teaching Hospitals Summary Physiology Epidemiology Definitions NICE guidelines Evaluation Conservative management Medical management
More informationPosterior Tibial Nerve Stimulation
Posterior Tibial Nerve Stimulation Policy Number: Original Effective Date: MM.02.025 01/01/2015 Lines of Business: Current Effective Date: HMO; PPO; QUEST Integration 02/01/2015 Section: Medicine Place(s)
More informationOffice based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2
Office based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2 1 The Male Health Centre, Oakville, Ontario, Canada 2 Humber River Regional Hospital, University of Toronto, Toronto,
More informationNeurogenic bladder. Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder.
Definition: Neurogenic bladder Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder. Types: Nervous system diseases: Congenital: like myelodysplasia like meningocele.
More informationUrodynamic Results of Sacral Neuromodulation Correlate with Subjective Improvement in Patients with an Overactive Bladder
European Urology European Urology 43 (2003) 282±287 Urodynamic Results of Sacral Neuromodulation Correlate with Subjective Improvement in Patients with an Overactive Bladder W.A. Scheepens a, G.A. van
More informationEfficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder
Urol Sci 21;21(1):38 43 ORIGINAL ARTICLE Efficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder Yih-Chou Chen, Chia-Yen Chen, Hann-Chorng
More informationTools for Evaluation. Urodynamics Case Studies. Case 1. Evaluation. Case 1. Bladder Diary SUI 19/01/2018
Urodynamics Case Studies Christopher K. Payne, MD Vista Urology & Pelvic Pain Partners Emeritus Professor of Urology, Stanford University Tools for Evaluation Ears, Eyes, and Brain Bladder diary Stress
More informationComparative Study of Solifenecin Alone Versus Solifenecin with Duloxetine in Patients of Overactive Bladder
International Journal of Scientific and Research Publications, Volume 3, Issue 1, January 2013 1 Comparative Study of Solifenecin Alone Versus Solifenecin with Duloxetine in Patients of Overactive Bladder
More informationINCONTINENCE. Continence and Pelvic Floor Rehabilitation TYPES OF INCONTINENCE STRESS INCONTINENCE STRESS INCONTINENCE STRESS INCONTINENCE 11/08/2015
INCONTINENCE Continence and Pelvic Floor Rehabilitation Dr Irmina Nahon PhD Pelvic Floor Physiotherapist www.nahonpfed.com.au Defined as the accidental and inappropriate passage of urine or faeces (ICI
More informationWhat should we consider before surgery? BPH with bladder dysfunction. Inje University Sanggye Paik Hospital Sung Luck Hee
What should we consider before surgery? BPH with bladder dysfunction Inje University Sanggye Paik Hospital Sung Luck Hee Diagnostic tests in three categories Recommendation: there is evidence to support
More informationNormal micturition involves complex
NEW TARGET FOR INTERVENTION: THE NEUROUROLOGY CONNECTION * Donald R. Ostergard, MD, FACOG ABSTRACT Urine storage and release are under the control of the parasympathetic, sympathetic, and somatic nervous
More informationOveractive Bladder (OAB) and Quality of Life
Overactive Bladder (OAB) and Quality of Life Dr. Byron Wong MBBS (Sydney), FRCSEd, FRCSEd (Urol), FCSHK, FHKAM (Surgery) Specialist in Urology Central Urology Clinic Hong Kong Continence Society Annual
More informationSimplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder.
Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. Mattiasson, Anders; Blaakaer, J; Høye, K; Wein, A J Published in: BJU International DOI: 1.146/j.1464-41X.23.376.x
More informationMechanisms of Disease: central nervous system involvement in overactive bladder syndrome
Mechanisms of Disease: central nervous system involvement in overactive bladder syndrome Karl-Erik Andersson SUMMARY The pathophysiology of overactive bladder syndrome (OABS) and detrusor overactivity
More informationStimulation of the Sacral Anterior Root Combined with Posterior Sacral Rhizotomy in Patients with Spinal Cord Injury. Original Policy Date
MP 7.01.58 Stimulation of the Sacral Anterior Root Combined with Posterior Sacral Rhizotomy in Patients with Spinal Cord Injury Medical Policy Section Issue 12:2013 Original Policy Date 12:2013 Last Review
More informationSafety and Pain-relief Efficacy of Urethral Catheter with Local-anesthetic Injection Port
Shinshu Med J, 65⑹:355~359, 2017 Safety and Pain-relief Efficacy of Urethral Catheter with Local-anesthetic Injection Port Teppei Yamamoto *, Masashi Shiozaki, Yuji Shimojima, Tomomi Haba Tomohiko Oguchi,
More informationCross-sectional and longitudinal studies on interaction between bladder compliance and outflow obstruction in men with benign prostatic hyperplasia
Asian J Androl 2007; 9 (1): 51 56 DOI: 10.1111/j.1745-7262.2007.00221.x www.asiaandro.com. Original Article. Cross-sectional and longitudinal studies on interaction between bladder compliance and outflow
More informationVarious Types. Ralph Boling, DO, FACOG
Various Types Ralph Boling, DO, FACOG The goal of this lecture is to increase assessment and treatment abilities for physicians managing urinary incontinence (UI) patients. 1. Effectively communicate with
More informationDiagnosis and Treatment of Overactive Bladder
Diagnosis and Treatment of Overactive Bladder Case study: Mr. Lin I I have started to rush out of meetings to go to the toilet I I need to void every one hour I I used to be quite active. This is becoming
More informationPRE-OPERATIVE URODYNAMIC
PRE-OPERATIVE URODYNAMIC STUDIES: IS THERE VALUE IN PREDICTING POST-OPERATIVE STRESS URINARY INCONTINENCE IN WOMEN UNDERGOING PROLAPSE SURGERY? Dr K Janse van Rensburg Dr JA van Rensburg INTRODUCTION POP
More informationOveractive bladder can result from one or more of the following causes:
Overactive bladder can affect people of any age; however, it is more common in older people. Effective treatments are available and seeing your doctor for symptoms of overactive bladder often results in
More informationAbstract. Key words Trial without catheter, Acute urinary retention, Benign prostatic hyperplasia, Introduction
The role of sustained-released alfuzosin in the treatment of acute urinary retention Mohamed Fawzi Ahmed. Department of Surgery, Ninevah College of Medicine, University of Mosul. Abstract To see whether
More informationThe new International Continence Society
ROLE OF CYSTOMETRY IN EVALUATING PATIENTS WITH OVERACTIVE BLADDER ADAM J. FLISSER AND JERRY G. BLAIVAS ABSTRACT Overactive bladder (OAB) can be caused by a variety of conditions. We believe that cystometrography
More informationPhysiology & Neurophysiology of lower U.T.
Physiology & Neurophysiology of lower U.T. Classification of voiding dysfunction Evaluation of a child with voiding dysfunction Management Storage Ø Adequate volume of urine Ø At LOW pressure Ø With NO
More informationBotulinum Toxin: Applications in Urology
Botulinum Toxin: Applications in Urology Dr. Lee Jonat, PGY-4 Department of Urologic Sciences University of British Columbia Outline Mechanism of Action Technical Considerations Adverse Events Neurogenic
More informationGUIDELINES ON URINARY INCONTINENCE
GUIDELINES ON URINARY INCONTINENCE 9 J. Thüroff, (chairman), P. Abrams, J-T. Andersen, W. Artibani, E. Chartier-Kastler, C. Hampel, M. Hohenfellner, T. Tammela, Ph. van Kerrebroeck Introduction The condition
More informationDuloxetine in women awaiting surgery
DOI: 1.1111/j.1471-528.6.879.x www.blackwellpublishing.com/bjog Review article H Drutz Ontario Power Generation Building, Toronto, Ontario, Canada Correspondence: Prof. Dr H Drutz, Mount Sinai Hospital,
More informationFlowmetry/ pelvic floor electromyographic findings in patients with detrusor overactivity
ORIGINAL ARTICLE Vol. 41 (3): 521-526, May - June, 2015 doi: 10.1590/S1677-5538.IBJU.2014.0204 Flowmetry/ pelvic floor electromyographic findings in patients with detrusor overactivity Farshid Alizadeh
More informationGUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION
GUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION M. Stöhrer (chairman), D. Castro-Diaz, E. Chartier-Kastler, G. Kramer, A. Mattiasson, J-J. Wyndaele Introduction NLUTD (neurogenic lower urinary
More informationEfficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study
LUTS () 3, 36 4 ORIGINAL ARTICLE Efficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study Naoki WADA, Masaki WATANABE, Masafumi
More informationBrief Reports. Cystometric Evaluation of Voiding Dysfunctions
Brief Reports Cystometric Evaluation of Voiding Dysfunctions Pawanindra Lal Navneet Kaur Anurag Krishna Not infrequently, in pediatric practice one is confronted by anxious parents of children with voiding
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationUrodynamic findings in women with insensible incontinence
bs_bs_banner International Journal of Urology (2013) 20, 429 433 doi: 10.1111/j.1442-2042.2012.03146.x Original Article: Clinical Investigation Urodynamic findings in women with insensible Benjamin M Brucker,
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 4: , 2012
1112 Usefulness of total bladder capacity and post void residual urine volume as a predictor of detrusor overactivity with impaired contractility in stroke patients SANG HYUB LEE, JOONG GEUN LEE, GYEONG
More informationSolifenacin significantly improves all symptoms of overactive bladder syndrome
REVIEW doi: 10.1111/j.1742-1241.2006.01067.x Solifenacin significantly improves all symptoms of overactive bladder syndrome C. R. CHAPPLE, 1 L. CARDOZO, 2 W. D. STEERS, 3 F. E. GOVIER 4 1 Department of
More informationSignal transduction underlying the control of urinary bladder smooth muscle tone Puspitoayu, E.
UvA-DARE (Digital Academic Repository) Signal transduction underlying the control of urinary bladder smooth muscle tone Puspitoayu, E. Link to publication Citation for published version (APA): Puspitoayu,
More informationUrodynamics in Neurological Lower Urinary Tract Dysfunction. Mr Chris Harding Consultant Urologist Freeman Hospital Newcastle-upon-Tyne
Urodynamics in Neurological Lower Urinary Tract Dysfunction Mr Chris Harding Consultant Urologist Freeman Hospital Newcastle-upon-Tyne Learning Objectives Review functional neurology relevant to lower
More informationUrodynamic outcome of parasacral transcutaneous electrical neural stimulation for overactive bladder in children
ORIGINAL ARTICLE Vol. 41 (4): 739-743, July - August, 2015 doi: 10.1590/S1677-5538.IBJU.2014.0303 Urodynamic outcome of parasacral transcutaneous electrical neural stimulation for overactive bladder in
More informationBladder dysfunction in ALD and AMN
Bladder dysfunction in ALD and AMN Sara Simeoni, MD Department of Uro-Neurology National Hospital for Neurology and Neurosurgery Queen Square, London 10:15 Dr Sara Simeoni- Bladder issues for AMN patients
More informationUrethral pressure measurement in stress incontinence: does it help?
Int Urol Nephrol (2009) 41:491 495 DOI 10.1007/s11255-008-9506-9 UROLOGY - ORIGINAL PAPER Urethral pressure measurement in stress incontinence: does it help? Bassem S. Wadie Æ Ahmed S. El-Hefnawy Received:
More informationUrinary Incontinence for the Primary Care Provider
Urinary Incontinence for the Primary Care Provider Diana J Scott FNP-BC https://youtu.be/gmzaue1ojn4 1 Assessment of Urinary Incontinence Urge Stress Mixed Other overflow, postural, continuous, insensible,
More informationBJUI. Validity and reliability of the patient s perception of intensity of urgency scale in overactive bladder
; 2010 Lower Urinary Tract PATIENT S PERCEPTION OF INTENSITY OF URGENCY SCALE IN OAB CARTWRIGHT ET AL. BJUI Validity and reliability of the patient s perception of intensity of urgency scale in overactive
More informationRecommandations de prise en charge des vessies neurogènes EAU 2006
Annexe 4-1 Recommandations de prise en charge des vessies neurogènes EAU 2006 (Version courte) 685 686 GUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION M. Stöhrer (chairman), D. Castro-Diaz, E.
More informationBIOFEEDBACK TRAINING FOR DETRUSOR OVERACTIVITY IN CHILDREN
0022-5347/00/1645-1686/0 THE JOURNAL OF UROLOGY Vol. 164, 1686 1690, November 2000 Copyright 2000 by AMERICAN UROLOGICAL ASSOCIATION, INC. Printed in U.S.A. BIOFEEDBACK TRAINING FOR DETRUSOR OVERACTIVITY
More informationBotulinum-AToxin Detrusor and Sphincter Injection in Treatment of Overactive Bladder Syndrome: Objective Outcome and Patient Satisfaction
European Urology European Urology 48 (2005) 984 990 Botulinum-AToxin Detrusor and Sphincter Injection in Treatment of Overactive Bladder Syndrome: Objective Outcome and Patient Satisfaction Heinrich Schulte-Baukloh
More informationEfficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study
Efficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study Yoshihisa Matsukawa,* Momokazu Gotoh, Tomonori Komatsu, Yasuhito Funahashi, Naoto Sassa and Ryohei Hattori
More informationSELECTED POSTER PRESENTATIONS
SELECTED POSTER PRESENTATIONS The following summaries are based on posters presented at the American Urogynecological Society 2004 Scientific Meeting, held July 29-31, 2004, in San Diego, California. CENTRAL
More informationManagement of Female Stress Incontinence
Management of Female Stress Incontinence Dr. Arvind Goyal Associate Professor (Urology& Renal Transplant) Dayanand Medical College & Hospital, Ludhiana, Punjab, India Stress Incontinence Involuntary loss
More informationUrogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018
Urogynecology in EDS Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018 One in three like me Voiding Issues Frequency/Urgency Urinary Incontinence neurogenic bladder Neurologic supply
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationUrinary incontinence (UI) affects as many
EXPLORING NEW HORIZONS IN STRESS INCONTINENCE: THE NEUROUROLOGY CONNECTION W. Glenn Hurt, MD* ABSTRACT As many as one-third of women are affected by urinary incontinence, the most common of which being
More informationMr. GIT KAH ANN. Pakar Klinikal Urologi Hospital Kuala Lumpur.
Mr. GIT KAH ANN Pakar Klinikal Urologi Hospital Kuala Lumpur drgitka@yahoo.com 25 Jan 2007 HIGHLIGHTS Introduction ICS Definition Making a Diagnosis Voiding Chart Investigation Urodynamics Ancillary Investigations
More informationDrug Class Review on Urinary Incontinence Drugs
Drug Class Review on Urinary Incontinence Drugs FINAL REPORT February 2003 Marian S. McDonagh, PharmD Produced by Oregon Evidence-based Practice Center Oregon Health & Science University 3181 SW Sam Jackson
More informationUrinary Incontinence. Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital
Urinary Incontinence Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital Affects women of all ages Impacts physical, psychological & social wellbeing Impact on families & carers Costs the
More informationEfficacy of botulinum-a toxin in the treatment of detrusor overactivity incontinence: A prospective nonrandomized study
American Journal of Obstetrics and Gynecology (2005) 192, 1735 40 www.ajog.org Efficacy of botulinum-a toxin in the treatment of detrusor overactivity incontinence: A prospective nonrandomized study Matthias
More information